1. Show article details.

    Charles River Laboratories to Present at Upcoming Investor Conferences

    Business Wire – 8:30 AM ET 11/11/2019

    Charles River Laboratories International, Inc. (CRL) announced today that it will present at three upcoming investor conferences, including: Management will present an overview of Charles River’s strategic focus and business developments.

  2. Show article details.

    BRIEF-Charles River Laboratories Q3 Non-GAAP Earnings Per Share $1.69

    Reuters – 7:52 AM ET 11/06/2019

    Charles River Laboratories International Inc (CRL): * CHARLES RIVER LABORATORIES ANNOUNCES THIRD-QUARTER 2019 RESULTS. * Q3 NON-GAAP EARNINGS PER SHARE $1.69. * Q3 GAAP EARNINGS PER SHARE $1.46. * Q3 REVENUE $668 MILLION VERSUS REFINITIV IBES ESTIMATE OF $672.7 MILLION. * Q3 EARNINGS PER SHARE ESTIMATE $1.63 -- REFINITIV IBES DATA. * COMPANY IS UPDATING 2019 FINANCIAL GUIDANCE.

  3. Show article details.

    Charles River Laboratories Announces Third-Quarter 2019 Results

    Business Wire – 7:00 AM ET 11/06/2019

    – Third-Quarter Revenue of $668.0 Million – – Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 – – Updates 2019 Guidance – Charles River Laboratories International, Inc. (CRL) today reported its results for the third quarter of 2019. Acquisitions, which principally included Citoxlab, contributed 7.5% to consolidated third-quarter revenue growth.

  4. Show article details.

    BRIEF-Charles River Laboratories Says Co Entered Into A Second Supplemental Indenture To Base Indenture Dated April 3

    Reuters – 5:20 PM ET 10/23/2019

    Charles River Laboratories International Inc (CRL): * Charles River Laboratories International Inc (CRL) - ON OCTOBER 23, ENTERED INTO A SECOND SUPPLEMENTAL INDENTURE TO BASE INDENTURE DATED APRIL 3, 2018 Source text: Further company coverage:

  5. Show article details.

    Charles River Laboratories Announces Closing of Senior Notes Offering

    Business Wire – 4:30 PM ET 10/23/2019

    Charles River Laboratories International, Inc. (CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 in an unregistered offering. The notes have not been, and will not be, registered under the Securities Act of 1933, as amended, or under the securities laws of any other jurisdiction.

  6. Show article details.

    Charles River Laboratories Schedules Third-Quarter 2019 Earnings Release and Conference Call

    Business Wire – 4:30 PM ET 10/21/2019

     . Charles River Laboratories International, Inc. (CRL) will release third-quarter 2019 financial results on Wednesday, November 6th, before the market opens. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

  7. Show article details.

    BRIEF-Charles River Laboratories Says Intends To Offer $500 Mln In Senior Notes Due 2028

    Reuters – 8:22 AM ET 10/21/2019

    Charles River Laboratories International Inc (CRL): * CHARLES RIVER LABORATORIES (CRL) - INTENDS TO OFFER $500 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2028. * CHARLES RIVER LABORATORIES (CRL) - INTENDS TO USE NET PROCEEDS OF NOTES OFFERING, CASH TO PREPAY PORTION OF ITS TERM LOAN FACILITY Source text for Eikon: Further company coverage:

  8. Show article details.

    Charles River Laboratories Announces Offering of $500 Million of Senior Notes

    Business Wire – 8:05 AM ET 10/21/2019

    Charles River Laboratories International, Inc. (CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 in an unregistered offering, subject to market conditions.

  9. Show article details.

    Charles River Laboratories Demonstrates Industry-Leading Research at Neuroscience 2019

    Business Wire – 4:30 PM ET 10/16/2019

    Charles River Laboratories International, Inc. (CRL) today announced that its team of neuroscience drug discovery experts will present 37 scientific posters, both independently and collaboratively with clients, at Neuroscience 2019, the annual meeting of the Society for Neuroscience.

  10. Show article details.

    Charles River Laboratories Joins Dementia Consortium, Reaffirms Commitment to Neuroscience Research

    Business Wire – 8:00 AM ET 10/03/2019

    Charles River Laboratories International, Inc. (CRL) announced today that the Company has been selected by Alzheimer’s Research UK to join the Dementia Consortium. The Consortium invests in academic led research projects, typically 2-3 years in duration, which aim to provide validation of targets for the treatment of dementia or explore the tractability of the target for drug discovery.

  11. Show article details.

    BRIEF-Charles River Laboratories International Increases Size Of Board To 11 From 10

    Reuters – 10:06 AM ET 10/01/2019

    Charles River Laboratories International Inc (CRL): * Charles River Laboratories International Inc (CRL) - INCREASED SIZE OF BOARD FROM TEN TO ELEVEN Source: Further company coverage:

  12. Show article details.

    Charles River Laboratories Adds Virginia M. Wilson to Board of Directors

    Business Wire – 8:00 AM ET 10/01/2019

    Charles River Laboratories International, Inc. (CRL) today announced the appointment of Virginia M. Wilson, the recently retired Senior Executive Vice President and Chief Financial Officer of Teachers Insurance and Annuity Association of America, to its Board of Directors.

  13. Show article details.

    Charles River Laboratories Announces Updates to Microbial Solutions Product Portfolio

    Business Wire – 8:00 AM ET 09/09/2019

    New EndoScan-V™ endotoxin detection software and Celsis® automated detection platform for rapid sterility introduced to address unmet industry needs Charles River Laboratories International, Inc. (CRL) today announced the launch of two new products in its Microbial Solutions portfolio: an updated EndoScan-V™ software platform for endotoxin detection and measurement; and the introduction of the Celsis...

  14. Show article details.

    Charles River Laboratories to Host 3rd Annual World Congress

    Business Wire – 4:30 PM ET 09/05/2019

    The two-day event will highlight strategies for delivering drugs to patients faster Charles River Laboratories International, Inc. (CRL) is proud to host the 3rd Annual World Congress: Delivering Therapies to the Clinic Faster on September 23-24, 2019 in Cambridge, Mass. This press release features multimedia.

  15. Show article details.

    Charles River Laboratories to Present at Baird and Morgan Stanley Investor Conferences

    Business Wire – 4:30 PM ET 09/03/2019

    - Company to Host an Investor Day on September 12th - Charles River Laboratories International, Inc. (CRL) announced today that it will present at the Baird 2019 Global Healthcare Conference in New York on Thursday, September 5th, at 10:15 a.m. EDT, and at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10th, at 10:00 a.m. EDT.

  16. Show article details.

    Agricor & Botanacor Name New COO. Dr. Carl Craig Will Lead Companies’ Continued Expansion for Lab Testing in the Cannabis and Hemp Sectors.

    Business Wire – 2:15 PM ET 08/27/2019

    Now Accepting Cannabis Test Samples from Colorado & Hemp Test Samples from All of North America, Agricor & Botanacor See Dramatic Growth, Which Dr. Craig Will Leverage into Broader Marketshare Agricor and Botanacor – sister lab-service companies – today announced the appointment of Dr. Carl Craig as the new C.O.O. for both companies.

Page:

Today's and Upcoming Events

  • Feb
    11

    CRL to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    06

    CRL announced Q3 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.